Inspira Technologies filed a Patent Application for Using the ART Device to support A Supportive Device, which can be used with the instrument's patented technology, can now be purchased with ARM
Inspira Technologies (NASDAQ: IINN) (NYSE: INNW), a specialty medical device company that specializes in the research, development, manufacturing and marketing of proprietary respiratory support technologies, announced today that it filed i
The supportive device is intended to provide safe treatment and mobilization for cannulated patients. This will allow the medical staff more flexibility in the implementing treatment procedures as well as to allow for a safe transfer of patients between hospitals and medical centers.
The device can also be potentially used in the treatment of thousands of patients who are treated each year by extracorporeal membrane oxygenation (ECMO) as well as additional treatments for COVID-19, chronic obstructive
Dagi Ben-Noon, CEO of Inspira, is Inspia's CEO. The revolutionary supportive device is likely to redefine treatment procedures and improve patient outcomes. The Company decided to file the patent in the Israeli Patent Office, since it is recognized as a leading International Search Authority. The route chosen by the Company makes it possible to obtain a patent in less than ten months (assuming the examiner determines this product is an innovative product). Israel's introductory law applies to the whole world, as well as bilateral agreements with countries around the world that will accept a certificate of the Israeli exam.
The ART device is a portable respiratory support system, which works as pulmonary lung. Inspira Technologies is developing regenerative immunotherapeutics. The ART device allows patients to remain awake during treatment, while also minimizing the use of highly invasive, risky and costly mechanical ventilation systems.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost-effective early extracorporeal respiratory support system with the intent of establishing 'artificial lung' to treat respiratory patients. The ART device designed to utilize a hemoprotective flow approach to improve patient sanity while they are awake and breathing, thereby reducing the patient's need for mechanical ventilation. The Company's product hasn't yet been tested or used in humans and has not been approved by the FDA.
For more information, please visit our corporate website.
Statements of the future - Expected Statement Disclaimers, statements and statements.
These press releases contain forward-looking statements express or implied in accordance with the U.S. Federal securities laws. For example, the Company uses forward-looking statements to describe the potential benefits of a supportive device and the possibility that the supportive devices will redefine treatment procedures. These forward-looking statements and their implications are based only on the actual expectations of the management of this Company and are subject to a number of factors and uncertainties that could result in actual results to differ materially from those described in the forward The Company undertakes no obligation to publicly release any changes to these forward-looking statements to reflect events or circumstances after the date hereof or to show the occurrence of unanticipated events. The Company's Registration Statement on Form F-1 filed with the SEC is available on the website of the Securities and Exchange Commission.
For more details, please:
Miri Segal, Investor Relations, MS-IR LLC+917-607-8654, [email protected]
Michak Efraty, Public Relations.+972-52-304-4404, [email protected]
SOURCE Inspira Technologies SURCE inspure technologies SOS - SURE Technologies Technologies.